Alzheimers 2023 | Amsterdam, The Netherlands | Netherlands Antilles | Allied Conferences | Meetings

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences

Theme

Advancements for the Supremacy of Alzheimer’s and Dementia

- Alzheimer's 2023

Welcome Message

On behalf of the International Scientific Committee, it is our immeasurable pleasure to welcome the dignitaries of the globe to solicit their praiseworthy presence at our 15^th International Conference on Alzheimer's Disease and Dementia which is scheduled from October 30-November 01, 2023 in Amsterdam, The Netherlands.

Alzheimers Disease Conferences 2023 brings forth academic researchers and professionals for the designation of an emerging and thought-provoking thesis for the future betterment of Alzheimer’s Disease and Dementia. In terms of neurodegenerative disorders, Alzheimer's disease progressed as the leading cause of death and a major contributor to physical impairment that calls for urgent medical attention.

Alzheimers Disease Conferences 2023 anticipates over 300+ attendees from all over the globe to attend thought-provoking Keynote talks, Oral & Poster presentations. This year's conference will provide several opportunities for all stakeholders who belongs to the arena of Dementia, Alzheimer’s disease, and neurodegenerative diseases.

Market Analysis

The current research analytics has improved a DBS location for the treatment of Alzheimer’s disease that may potentially be used in future clinical studies. Isolating a targetable network and demonstrating that it may be predictive of patient outcomes was intriguing because DBS has not yet been used to treat many Alzheimer's patients. The benefit of DBS may be more clearly demonstrated throughout the group if more patients are stimulated in this area. The researchers confirmed their findings in a test cohort of 18 patients, whose data had been omitted from the earlier phases of the study, using a methodology influenced by the machine-learning literature. Based on where the electrodes had been implanted during the patients' fx-DBS surgeries, they created a model that could precisely predict the clinical results in these 18 patients. The advancement of Alzheimer's disease is being tracked over time using a variety of innovative technology, which helps people retain and keep track of their activities. There are several potentials in the market for Alzheimer's Therapeutics due to rising R&D expenditure, continued development of novel medicines to treat, postpone, and prevent the illness, as well as early detection of the ailment.

The Alzheimer’s disease diagnostics and treatment market is valued at US $ 6,986.70 million in 2021 and is projected to reach the US $ 9,639.23 million by 2027, with a CAGR of 5.51% expected to grow during the forecast period. The scope of the global market for Alzheimer's treatments was estimated at USD 4.04 billion in 2021 and is anticipated to grow at a CAGR of 16.2% from 2022 to 2030. Alzheimer’s disease International (ADI) estimates that 75% of people with Dementia worldwide remain undiagnosed this is 41 million people. They state that in some low and middle-income countries where prejudice and lack of Dementia awareness is major barriers to diagnosis, the number can be as high as 90%. Biomarkers have become important developments, lowering the risk and improving therapeutic outcomes since there is a high risk connected with medications for Alzheimer's disease. In order to better understand the disease and the treatments being used to treat it, researchers are using biomarkers to pinpoint important biological occurrences. The use of biomarkers improves the drug development process by lowering the risks associated with drug development and increasing the value of choosing the best therapeutic candidates for big, pricey phase 3 clinical trials. As a result, biomarkers are being used more often. The market for Alzheimer's disease is seeing growing potential in terms of new medication therapy choices thanks to the discovery of novel biomarkers for therapeutic usage.

For every 3 seconds, someone on this planet is diagnosed with Dementia, 70% of which have been confirmed to have Alzheimer’s disease. It is estimated that 46.8 million people will live with Dementia care in 2017 and nearly 50 million in 2019. About this number doubles every 20 years, reaching 75 a million in 2030 and 131.5 million in 2050, according to a study that 58% of people with dementia live in low- and middle-income countries. But by 2050, that percentage will rise to 68%. The fastest aging population growth is occurring in China, India and their South Asian and Western Pacific neighbors. Vital aging is an overall process that marks the victory of medical improvement over the last century. Today, the proportion of older people in the population is high, as many people live longer and more profitable lives.

Dementia mainly affects the elderly, but cases that develop before the age of 65 are receiving increasing attention. Alzheimer’s disease is the most common form of Dementia. By 2050, there are projected to be more than 150 million instances of dementia globally, a sharp increase from the 50 million cases that exist today. A global epidemic of obesity, generally measured by body mass index (BMI), persists, and past research revealed that obesity in middle age may raise the risk of dementia. The link between BMI and the risk of dementia, however, is still not obvious. Researchers have discovered that a person's dementia risk may be indicated by varied patterns of BMI changes throughout the course of their lifetime. The world is divided into segments based on drug type and distribution method. The drug class is divided into three categories: cholinesterase inhibitors, glutamate inhibitors, and MAO inhibitors. Our market prediction for dementia medications indicated that the MAO inhibitors sub-segment held the bulk of the share from 2022 to 2030. Retail pharmacies, hospital pharmacies, and other types of pharmacies make up the distribution route. The hospital pharmacy sub-segment produced the most market share in 2021 and is anticipated to continue doing so in the years to come.

Alzheimer's Disease Conferences 2023 objective is to bring all existing and budding bio entrepreneurs together to share present and experiences of new challenges and innovations in Alzheimer's & Dementia community. Every year, over a million companies are started in the world with about 5–10 of them known as high technology companies. Changing ideas into business ventures is tricky opportunity-recognition step critical in new venture creation. Even though life scientists are the founders of biotech companies, studies have shown that most successful high-tech start-ups are founded by a team of two to three individuals with mixed backgrounds, substantial industry experience and a very clear market and product focus at founding. These two days conference will be a highly interactive forum that will bring experts in areas ranging from Alzheimer's disease analysis to novel therapeutic techniques and approaches to cure Alzheimer's disease. Our outstanding speakers will do talks for 25-30 min and Students do poster presentations from submitted abstracts. Interested business candidates will exhibit their products and some do Workshops.

About Alzheimers 2023

Alzheimers 2023 revolves around the theme of “Advancements for the Supremacy of Alzheimer’s and Dementia”

The present research survey explains that there are large-scale studies to discover new clues for the treatment of Dementia and Alzheimer’s disease. Through this conference, researchers can explore their new research surveys and clues for treating Alzheimer’s disease.

The motive of Alzheimers Disease Conferences 2023 is to manipulate the differential research ideas of scholars and to share their research experience while they are treating and taking care of patients who are affected due to Alzheimer’s disease. Join us in the event of Alzheimers Disease Conferences 2023 to experience the global ambiance with the research scholars to establish a partnership and to build your network among fellow researchers of Neurology and Neuroscience.

The stimulating sessions of Alzheimers Disease Conferences 2023 include Alzheimer’s Disease, Brain Injury and Dementia, Neurodegenerative Disorders, Amyloid protein in Dementia, Parkinson’s Disease, Vascular Dementia, and so on.

Target Audience:

Neuro Scientists
Neuro Surgeons
Research scholars of Neurology and Neuro Science
Neurologists
Dementia care providers
Healthcare professionals
Professors and Assistant professors
Students
Young Research Forums
Organizations related to Alzheimer’s Diseases
Marketing Executives

Benefits of Attending:

Showcase your desired innovations among expertise
Converse among the global research scholars and experts
Enlightening of expertise research work
Meet influencers and industrial experts face to face
Abstract Publication with unique DOI in our International Supporting Journal
Participation Certificate with OCM signature

Event Opportunities:

Keynote forum
Speaker Presentation
Lectures by the active Investigators
Sponsorship and Exhibitors
Pre-congress workshops
Global Networking
Symposiums

Awards & Appreciations:

Speaker Excellence Awards
Best E-Poster Awards
Young Research Award

Sessions & Tracks

Session on Alzheimer’s Disease:

The global effect of Alzheimer’s disease has increased by over 100,000 cases by the end of the 20^th century and accounts for 60 – 80% of Dementia cases. By the year 2022, approximately 6.5 billion people were affected by Alzheimer’s in the USA. The current survey explains that Alzheimer’s disease is at being the forefront of biomedical research and research scholars are initiating their approaches towards this disease in light of finding upgraded treatments to treat and control Alzheimer’s. This disease leads to the accumulation of abnormal proteins and the degeneration of nerve cells. Research scholars can explore their trending research to the world by taking part in our Alzheimers Conference 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Brain Injury and Dementia:

Brain injury is a major problem that is caused due to accidents and falls. The current of survey dementia proves that brain injury is major cause of the increased effect of dementia. Brain Injury also leads to Neurodegeneration and brain atrophy after the completion of 8 to 10 months from brain injury. The brain injury results in the building up of tau tangles and amyloid plaques which are similar to the microscopic changes which result in Alzheimer’s disease and other Dementia types. In this track, we will be discussing the major causes of brain injury which is the leading factor for the cause of dementia. Researchers are invited to explore their current ideologies through Alzheimers Disease Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Neurodegenerative Disorders:

Millions of people are affected by Neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington's disease, etc. This type of disorder encompasses conditions that result in intense damage to the cells and nervous system. Multidisciplinary approaches have been progressed by research scholars for the rehabilitation of physical and psychological management of neurodegenerative disorders. Alzheimers Disease Conferences 2023 waits for the involvement of research professionals to enrich their research findings for the betterment and treatment of neurodegenerative disorders.

Associated Conferences:

Related Associations:

Related Societies:

Session on Amyloid protein in Dementia:

The presence of harmful protein clumps in the brain is a common feature of dementia. These aggregates are made of proteins called amyloid and tau in Alzheimer's disease. The arteries of the brain is built by amyloid proteins which result in the cause of dementia which is a major risk factor the aged people above the age of 55. The major pathological factors such as senile plaques and neurofibrillary tangles are the main cause for dementia disease. In this session, we will be discussing how we can control the building of amyloid proteins in the brain through Alzheimer's Disease Conferences 2023.

Associated Conferences:

Related Associations:

Session on Parkinson’s and Huntington’s Disease:

A neurological disorder that affects the parts of the nervous system and brain. This dreadful disorder leads the patients to suffer with depression, behavioral changes, sleep problems, depression, memory difficulties, fatigue, and so on. The first and foremost symptom of Parkinson’s Disease is impairment of basal ganglia which causes the nerve cells to produce less dopamine. This disorder majorly affects the people with the age of above 50. The research experts can join the Alzheimers Disease Conferences 2023 to explore their findings and advancing treatmental procedures for the diagnosis of Parkinson’s Disease.

Associated Conferences:

Related Associations:

Related Societies:

Session on Vascular Dementia:

Vascular dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to the brain, depriving brain cells of vital oxygen and nutrients Inadequate blood flow can damage and eventually kill cells anywhere in the body. The brain has one of the body's richest networks of blood vessels and is especially vulnerable. In vascular dementia, changes in thinking skills sometimes occur suddenly following strokes that block major brain blood vessels. Alzheimer's Disease Conferences 2023 invites all global researchers to enhance their preliminary research for the better treatment of Vascular Dementia.

Associated Conferences:

Related Associations:

Related Societies:

Session on Lewy Body Dementia:

A type of neurological disorder that is associated with the abnormal deposition of a protein called alpha-synuclein in the brain which causes a progressive decline in mental abilities. The current survey explains that Lewy Body dementia affects more men than women. And also, it is stated that more than 1.4 million Americans are living a day-to-day life with Lewy Body dementia. In this session, we will be discussing about the current research findings for the controlment, treatment, diagnosis of Lewy Body Dementia through Alzheimers Disease Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Alzheimer’s and Dementia Patients Nursing Care:

In order to establish assisting communication with patients who are caused due to Alzheimer’s Disease and Dementia, a proper nursing care is needed for better treatment and diagnosis of Alzheimer's and Dementia. Better nursing care will encourage the patient for the undergoing of treatments, and exercises, and they will provide emotional support to the patient and his family. Research scholars can explore their trending research to the world by taking part in our Dementia Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Young Onset Dementia:

The current survey states around 900,000 people in the UK live with dementia, and the likelihood of developing dementia increases significantly with age among those 42,000 people suffering from Young Onset Dementia. Persons who suffer from dementia before the age of 60 are known as young onset dementia. Atypical forms of Alzheimer's disease are substantially more prevalent in younger people. Researchers are invited to showcase their research findings for the treatment, diagnosis, and nursing care through Dementia Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Dementia Care Aging Innovation:

Over the past twenty years, multiple interventions have been developed and examined to aid with the complex care needs of persons living with dementia care. Family caregivers of dementia patients encounter significant problems. Technological advancements are becoming more prevalent in studies on dementia patients. This session will focus on the advancement and innovations which are evolving for better treatment on Dementia and Alzheimer's disease.

Associated Conferences:

Related Associations:

Related Societies:

Session on Pain Management in Patients with Dementia:

People who are affected due to Alzheimer's disease and dementia will suffer severe physical pain due to deteriorating cognitive ability and brain function. Age-related pharmacokinetic and pharmacodynamic alterations have a significant impact on people who are affected with dementia. Paracetamol is a medicine that will control the pain in patients who are suffered from dementia and Alzheimer’s. Research scholars can explore their research innovations for the pain management of dementia by taking part in our Alzheimers Disease Conference 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Bio-Informatics approach for Alzheimer’s Disease:

The development of bioinformatics can be utilized to manage and assess data from the most recent high-throughput research methods and provide new ways to uncover the causes of neurodegenerative disorders. The current research survey focuses to implement their bioinformatics approach for the betterment of Alzheimer's disease and dementia. In this session, we invite the research professionals to explore their research innovations by soliciting their presence in Alzheimer's Disease Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Diagnosis and Prognosis of Alzheimer’s Disease:

Alzheimer's disease is usually diagnosed based on the person's medical history, history from relatives, and behavioral observations. The presence of characteristic neurological and neuropsychological features and the absence of alternative conditions is supportive. Currently, there are only a few medications for Alzheimer’s and they do not have the power to slow down the symptoms these medications do not reverse or cure the disease. Researchers are invited to showcase their research findings for the diagnosis and prognosis treatments through Dementia Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Alzheimer's Prevention and Risk factors:

Risk factors of Alzheimer’s are not known by scientists, but they have made a hypothesis of two known risk factors that is age and genetics. With age, it is identified that 60 % of people are affected and genetics has also been a major drawback. Other factors are stroke, depression, diabetes, head injury, hypothyroidism, and cardiovascular problem. Prevention involves eating a healthy diet and maintaining a good workout routine for the body and brain. In this track, we will be discussing the preventive measures and risk factors for the cause of Alzheimer’s disease and dementia. Researchers are invited to explore their current ideologies through Alzheimer's Disease Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Session on Technological Innovations for Caregivers:

People who help the diseased people with their day-to-day routine, being a companion in sharing their day. Most people become aggressive and uncontrollable, in this case, the family seeks the help of home care and caretakers. They are specially trained people who have the ability to take care of them. They even go to the extent to conduct social events so as to strip off their ideology of isolation. Researchers are invited to showcase their research findings and technological innovations through Alzheimer's Disease Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Optic Nerve Disorder in Alzheimer’s:

Optic neuritis occurs when swelling (inflammation) damages the optic nerve — a bundle of nerve fibers that transmits visual information from your eye to your brain. Common symptoms of optic neuritis include pain with eye movement and temporary vision loss in one eye. In this session we invite the research professionals to explore their research innovations by soliciting their presence in Dementia Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Alternative treatment for Alzheimer’s Disease:

As there is a lack of treatments to cure Alzheimer's disease and Dementia, doctors and researchers are finding alternative treatments for the controlled of Alzheimer's disease and Dementia. Alternative treatments such as Aromatherapy, Bright light therapy, Herbal medicine, and Acupuncture are helpful in controlling Alzheimer’s Disease. Researchers are invited to showcase their research findings and technological innovations through Alzheimer's Disease Conferences 2023.

Associated Conferences:

Related Associations:

Related Societies:

Artificial Intelligence in Dementia and Alzheimer’s:

The current research works for the treatment of Alzheimer's disease and dementia are majorly focusing in technological innovations like artificial intelligence. Research scholars are developing computer programs to find out the earliest signs of Dementia and Alzheimer’s disease. As cerebral biomarkers are very expensive and its un availability machine learning models are utilizing cerebral biomarkers for the identification of the disease. Dementia Conferences 2023 invites all global researchers to enhance their preliminary research in artificial intelligence and machine learning models.

Associated Conferences:

Related Associations:

Related Societies:

Metrics

Allied Group, one of the world's most renowned scientific conference organizers, has its own distinct voice in every sector of business, technology, and research. The extent to which a conference series reaches an online community has a direct impact on its success. Every global meeting, whether for research, academia, or industry, requires an internet audience.

The major participants in the Alzheimers disease and dementia conference are research people, academicians, research institutes, industrialists, and students from the subject of neurology. Conferences on Alzheimers disease and dementia have a high number of unique visitors and page views, proving to be a growing success.

Allied widens its boundaries by keeping each conference's proceedings on its separate conference webpages and official social media profiles. The international scientific and industrial communities are thus invited to attend the array of talks, discussions, product exhibitions, and alliances.

Organizing committee members

Michael Coroneos, MBBS, FRACS

Master CIME, Senior Neurosurgeon & Honorary Adjunct Associate Professor., Neurosurgery

University of Queensland, Australia

Sarah Crawford, PhD

Professor, Department of Biology

Southern Connecticut State University, USA

Dr. Rajendra D. Badgaiyan, MD

Psychiatrist and Cognitive Neuroscientist, Psychiatry and Behavioral Sciences

Richmond University Medical Center, USA

Michel Bourin, MD

Professor, Professor of Pharmacology

University of Nantes, France

Mr. Alejandro De la Parra Solomon

Executive Board Member of WAMS, The World Academy of Medical Sciences

WAMS (The World Academy of Medical Science), Mexico

Mohamed Fahmy Zeid, MD

Founder & President of Brain & Skull Egyptian Society, Neurosurgery

Alexandria University, Egypt

Dario Furnari

University of Exeter , United Kingdom, United Kingdom

Dr. Ian Martins

Australia

To Collaborate Scientific Professionals around the World

Conference Date	October 30-01, 2023
Poster Oppurtunity	Available
e-Poster Oppurtunity	Available

Testimonials

Birendra Kumar Bista

Chairman & Managing Director at Neuro Cardio & Multi specialty Hospital

It was a great, spending time with the like minded peoples from Neuroscience department in Alzheimer's and Dementia Conference.

Emeritus Radu Mutihac

Professor

The speakers in all sessions I attended were exceptional. I hope, I will attend this conference next year also! Thank you for understanding the importance and need for our ongoing education and peer connection in Alzheimer's and Dementia.

Dr. Kiminobu Sugaya

Professor and Head of Neuroscience

The case studies and best practices were great! It was a well planned conference, engaged presenters and small; I found great the fact that there were QA sessions for the participants to ask questions.